Sonoma Pharmaceuticals, Inc. (SNOA)
USD 2.46
(7.21%)
USD 2.46
(7.21%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -2.52 Million USD | 15.18% |
| 2023 | -2.97 Million USD | 50.72% |
| 2022 | -6.02 Million USD | -290.23% |
| 2021 | -1.54 Million USD | 30.19% |
| 2020 | -2.21 Million USD | 31.14% |
| 2019 | -3.21 Million USD | 66.21% |
| 2018 | -9.51 Million USD | 44.21% |
| 2017 | -17.05 Million USD | -131.83% |
| 2016 | -7.35 Million USD | -21.59% |
| 2015 | -6.04 Million USD | -13.43% |
| 2014 | -5.33 Million USD | 10.6% |
| 2013 | -5.96 Million USD | -5225.89% |
| 2012 | -112 Thousand USD | 93.87% |
| 2011 | -1.82 Million USD | 69.28% |
| 2010 | -5.94 Million USD | -274.78% |
| 2009 | -1.58 Million USD | 90.45% |
| 2008 | -16.59 Million USD | -51.27% |
| 2007 | -10.97 Million USD | -64.32% |
| 2006 | -6.67 Million USD | -273.07% |
| 2005 | -1.79 Million USD | 0.0% |
| 2003 | -177 Thousand USD | 76.83% |
| 2002 | -764 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.61 Million USD | 44.1% |
| 2024 Q3 | -2.02 Million USD | -25.14% |
| 2024 Q4 | -2.52 Million USD | -24.69% |
| 2024 FY | -2.52 Million USD | 15.18% |
| 2024 Q1 | -2.88 Million USD | 2.76% |
| 2023 FY | -2.97 Million USD | 50.72% |
| 2023 Q3 | -2.14 Million USD | 16.65% |
| 2023 Q2 | -2.57 Million USD | 44.39% |
| 2023 Q4 | -2.97 Million USD | -38.31% |
| 2023 Q1 | -4.63 Million USD | 23.14% |
| 2022 FY | -6.02 Million USD | -290.23% |
| 2022 Q4 | -6.02 Million USD | 17.63% |
| 2022 Q3 | -7.31 Million USD | -5.98% |
| 2022 Q2 | -6.9 Million USD | -1707.85% |
| 2022 Q1 | -382 Thousand USD | 75.28% |
| 2021 Q3 | -3.56 Million USD | -54.51% |
| 2021 Q2 | -2.3 Million USD | 12.09% |
| 2021 FY | -1.54 Million USD | 30.19% |
| 2021 Q1 | -2.62 Million USD | -18.44% |
| 2021 Q4 | -1.54 Million USD | 56.6% |
| 2020 Q3 | -2.62 Million USD | -38.44% |
| 2020 FY | -2.21 Million USD | 31.14% |
| 2020 Q1 | -2.7 Million USD | 15.93% |
| 2020 Q4 | -2.21 Million USD | 15.82% |
| 2020 Q2 | -1.89 Million USD | 29.72% |
| 2019 Q3 | -6.29 Million USD | -68.69% |
| 2019 FY | -3.21 Million USD | 66.21% |
| 2019 Q1 | -7.2 Million USD | 24.24% |
| 2019 Q2 | -3.73 Million USD | 48.24% |
| 2019 Q4 | -3.21 Million USD | 48.92% |
| 2018 Q2 | -9.53 Million USD | 21.3% |
| 2018 FY | -9.51 Million USD | 44.21% |
| 2018 Q4 | -9.51 Million USD | -15.27% |
| 2018 Q3 | -8.25 Million USD | 13.46% |
| 2018 Q1 | -12.11 Million USD | 28.93% |
| 2017 FY | -17.05 Million USD | -131.83% |
| 2017 Q4 | -17.05 Million USD | 9.89% |
| 2017 Q3 | -18.92 Million USD | -495.81% |
| 2017 Q2 | -3.17 Million USD | 35.24% |
| 2017 Q1 | -4.9 Million USD | 33.32% |
| 2016 FY | -7.35 Million USD | -21.59% |
| 2016 Q2 | -7.97 Million USD | 8.52% |
| 2016 Q1 | -8.71 Million USD | -44.11% |
| 2016 Q3 | -6.11 Million USD | 23.34% |
| 2016 Q4 | -7.35 Million USD | -20.32% |
| 2015 Q3 | -2.23 Million USD | 36.91% |
| 2015 Q2 | -3.54 Million USD | 28.07% |
| 2015 Q1 | -4.92 Million USD | 7.69% |
| 2015 Q4 | -6.04 Million USD | -170.77% |
| 2015 FY | -6.04 Million USD | -13.43% |
| 2014 Q2 | -2.09 Million USD | 47.9% |
| 2014 Q4 | -5.33 Million USD | -57.41% |
| 2014 Q1 | -4.02 Million USD | 32.49% |
| 2014 Q3 | -3.38 Million USD | -61.49% |
| 2014 FY | -5.33 Million USD | 10.6% |
| 2013 Q1 | -1.47 Million USD | -1217.86% |
| 2013 Q4 | -5.96 Million USD | -18.35% |
| 2013 Q3 | -5.04 Million USD | 12.21% |
| 2013 Q2 | -5.74 Million USD | -288.96% |
| 2013 FY | -5.96 Million USD | -5225.89% |
| 2012 Q1 | -2.11 Million USD | -15.88% |
| 2012 FY | -112 Thousand USD | 93.87% |
| 2012 Q4 | -112 Thousand USD | 93.51% |
| 2012 Q3 | -1.72 Million USD | -61.55% |
| 2012 Q2 | -1.06 Million USD | 49.48% |
| 2011 FY | -1.82 Million USD | 69.28% |
| 2011 Q4 | -1.82 Million USD | 14.71% |
| 2011 Q3 | -2.14 Million USD | 40.56% |
| 2011 Q1 | -4.9 Million USD | 17.55% |
| 2011 Q2 | -3.6 Million USD | 26.5% |
| 2010 Q2 | -6.24 Million USD | -245.22% |
| 2010 Q4 | -5.94 Million USD | -19.53% |
| 2010 Q3 | -4.97 Million USD | 20.37% |
| 2010 FY | -5.94 Million USD | -274.78% |
| 2010 Q1 | -1.8 Million USD | -14.06% |
| 2009 Q2 | -4.7 Million USD | 51.52% |
| 2009 Q4 | -1.58 Million USD | 3.47% |
| 2009 FY | -1.58 Million USD | 90.45% |
| 2009 Q1 | -9.69 Million USD | 41.57% |
| 2009 Q3 | -1.64 Million USD | 65.06% |
| 2008 Q1 | -5.28 Million USD | 51.85% |
| 2008 Q2 | -12.05 Million USD | -128.18% |
| 2008 Q3 | -7.86 Million USD | 34.79% |
| 2008 Q4 | -16.59 Million USD | -111.13% |
| 2008 FY | -16.59 Million USD | -51.27% |
| 2007 FY | -10.97 Million USD | -64.32% |
| 2007 Q3 | 5.58 Million USD | 136.54% |
| 2007 Q2 | 2.35 Million USD | 0.0% |
| 2007 Q4 | -10.97 Million USD | -296.65% |
| 2006 Q4 | -6.67 Million USD | 0.0% |
| 2006 FY | -6.67 Million USD | -273.07% |
| 2005 Q4 | -1.79 Million USD | 0.0% |
| 2005 FY | -1.79 Million USD | 0.0% |
| 2003 FY | -177 Thousand USD | 76.83% |
| 2002 FY | -764 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 236.828% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 103.362% |
| Journey Medical Corporation | -9.7 Million USD | 74.045% |
| Embecta Corp. | 1.31 Billion USD | 100.192% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 100.549% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 100.582% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 83.882% |
| Alpha Teknova, Inc. | 1.97 Million USD | 227.66% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 102.675% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 100.579% |
| Cosmos Health Inc. | 8.59 Million USD | 129.334% |
| Dynavax Technologies Corporation | 106.63 Million USD | 102.363% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 98.074% |
| PainReform Ltd. | -7.95 Million USD | 68.302% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 83.882% |
| SCYNEXIS, Inc. | -19.35 Million USD | 86.977% |
| Safety Shot Inc | -2.28 Million USD | -10.315% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 73.276% |
| Procaps Group, S.A. | 242.93 Million USD | 101.037% |
| Theratechnologies Inc. | 24.87 Million USD | 110.132% |
| Harrow Health, Inc. | 116.41 Million USD | 102.165% |
| Biofrontera Inc. | 4.05 Million USD | 162.13% |
| DURECT Corporation | -7.65 Million USD | 67.076% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 92.484% |
| Cronos Group Inc. | -663.32 Million USD | 99.62% |
| OptiNose, Inc. | 58.06 Million USD | 104.34% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 100.404% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 82.707% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 51.408% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 116.785% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 60.375% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 2458.248% |
| Radius Health, Inc. | 359.28 Million USD | 100.701% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 1377.832% |
| ProPhase Labs, Inc. | 19.23 Million USD | 113.104% |
| Phibro Animal Health Corporation | 454.84 Million USD | 100.554% |
| Procaps Group S.A. | 242.93 Million USD | 101.037% |
| Alvotech | 1.06 Billion USD | 100.237% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 168.515% |
| Viatris Inc. | 17.13 Billion USD | 100.015% |
| Rockwell Medical, Inc. | 4.45 Million USD | 156.553% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 48.329% |
| SIGA Technologies, Inc. | -148.68 Million USD | 98.305% |
| Tilray Brands, Inc. | 158.97 Million USD | 101.585% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 102.067% |
| Shineco, Inc. | 29.29 Million USD | 108.604% |
| PetIQ, Inc. | 351.93 Million USD | 100.716% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 13.146% |
| Incannex Healthcare Limited | -5.48 Million USD | 54.057% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 101.421% |
| Alimera Sciences, Inc. | 55.3 Million USD | 104.556% |
| Silver Spike Investment Corp. | -32.61 Million USD | 92.273% |
| Assertio Holdings, Inc. | -32.52 Million USD | 92.253% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -69.273% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 50.201% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 47.653% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 69.319% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 159.758% |
| Hempacco Co., Inc. | 13.61 Million USD | 118.509% |
| Talphera, Inc. | -5.72 Million USD | 55.952% |
| Alvotech | 1.06 Billion USD | 100.237% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 135.269% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 97.394% |
| Currenc Group, Inc. | -16.57 Million USD | 84.795% |
| Kamada Ltd. | -46.43 Million USD | 94.573% |
| Indivior PLC | -33.95 Million USD | 92.578% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 1067.096% |
| Flora Growth Corp. | -713 Thousand USD | -253.436% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 69.319% |
| Evolus, Inc. | 63.7 Million USD | 103.956% |
| HUTCHMED (China) Limited | -197.45 Million USD | 98.724% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 100.526% |
| Akanda Corp. | 3.9 Million USD | 164.534% |